Published in Hepatitis Weekly, June 8th, 2009
"We designed a pilot Study to determine the initial and 12-week posttreatment viral response. A nonrandomized. prospective observational study of adjusted-dose combination therapy. Twenty patients were enrolled and began pegylated interferon at 135 mu g/wk SC, and 4 weeks later ribavirin was started at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.